By Adriano Marchese
Eupraxia Pharmaceuticals shares rose in premarket trading Tuesday after the company said it received positive data from its eosinophilic esophagitis treatment trials.
Shares traded nearly 6.3% higher in New York at $4.00.
The Toronto and New York-listed biotechnology company said that all three patients that were part of the Resolve phase 1b/2a trial evaluating EP-104GI as a treatment reported reduced symptom severity.
Eosinophilic esophagitis, or EoE, is a chronic immune system disease where a type of white blood cell, called an eosinophil, builds up in the lining of the esophagus and causes averse reactions to certain foods or allergens.
The trial also showed that there was improvement in tissue health among the patients, the largest improvement observed in any of the cohorts to date.
Eupraxia said that these effects are comparable to, or better than, what has been demonstrated by currently approved treatments for EoE.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 25, 2025 09:30 ET (14:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.